Prefilled Syringes Market to Reach $6.75 Billion by 2035 at 5.6% CAGR | Becton Dickinson, SCHOTT AG, Stevanato Among Key Players

The global prefilled syringes market, valued at USD 3.81 billion in 2025, will grow to USD 4.12 billion in 2026 and reach USD 6.75 billion by 2035, advancing at a CAGR of 5.6% across the 2026-2035 forecast period. This steady expansion reflects accelerating demand for self-injection devices, the rapid commercialization of biologics and biosimilars, and a fundamental shift in chronic disease management toward home-based care. For pharmaceutical manufacturers, drug delivery companies, and healthcare investors, the prefilled syringes market now represents one of the most structurally sound growth opportunities in parenteral drug packaging.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/prefilled-syringes-market/request-sample.html

Market Overview
Prefilled syringes are primary packaging systems that come pre-loaded with a precise, ready-to-inject dose of parenteral medication. By eliminating the manual filling step, they reduce contamination risk, minimize drug wastage, and deliver measurable gains in dose accuracy. Three main formats have gained clinical traction: dual chamber syringes, which store liquid and lyophilized components separately to preserve drug stability; flush syringes, which clear intravenous catheters and vascular access devices; and safety syringes, which incorporate needle protection mechanisms to prevent accidental needlestick injuries.

The market gains urgency from the scale of chronic disease globally. In the US alone, close to 133 million people currently live with one or more chronic conditions, and that figure is projected to climb to 170 million by 2030. The US Centers for Disease Control estimates the annual economic burden of chronic diseases at USD 4.1 trillion. Prefilled syringes address this burden directly by supporting self-administration in home settings, reducing the number of clinical visits, and improving patient adherence for conditions such as rheumatoid arthritis, diabetes, and blood disorders.

Capital deployment in this space has been decisive. In August 2025, Becton Dickinson committed USD 35 million to expand manufacturing capacity for its PosiFlush prefilled syringes at its Nebraska facility. A month earlier, INCOG invested USD 125 million in a new 100,000-square-foot manufacturing facility in Fishers, Indiana, specifically to meet growing demand for biopharmaceutical drug-device combination systems. These are not speculative bets; they are capacity investments responding to confirmed order pipelines.

Key Growth Drivers
Rising Prevalence of Chronic Diseases and Self-Injection Demand The growing global burden of autoimmune disorders, cardiovascular conditions, oncological diseases, and diabetes is generating sustained demand for parenteral therapies that patients can administer without clinical supervision. Prefilled syringes are the preferred delivery format for many of these treatments because they offer accurate dosing, ease of use, and a lower contamination risk than traditional vials. As patients and payers alike push for cost-effective, home-compatible care, the device category benefits directly.

Accelerating Biosimilar and Biologic Launches The 2024 commercial calendar illustrated the strategic alignment between new biologic launches and prefilled syringe format adoption. Biocon Biologics launched its Yesafili biosimilar in Canada in March 2024; Amgen Korea launched a prefilled syringe format for Xgeva in July 2024; STADA and Alvotech brought the Stelara biosimilar Uzprovo to Europe in the same month. In August 2025, Accord BioPharma launched its IMULDOSA biosimilar of Stelara in prefilled syringe format in the US. This commercial pattern is structural, not cyclical. As biologic patent cliffs accelerate through 2030, biosimilar manufacturers will default to prefilled syringe formats to match the originator's patient experience and physician familiarity.

Regulatory Approvals Expanding Clinical Indications In April 2025, Argenx received regulatory approval for a prefilled syringe format of efgartigimod (Vyvgart) for patients with generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Each such approval extends the addressable patient population for prefilled formats and signals to the broader market that regulators are increasingly receptive to drug-device combinations that favor patient self-administration.

Expanding IP Portfolio and Technological Innovation More than 1,300 patents have been filed in the prefilled syringes domain since 2019, with approximately 40% already granted. Becton Dickinson leads in patent filings, followed by Terumo and Sanofi. The focus areas span patient safety mechanisms, dosing error elimination, smart tracking technologies, and materials innovation. SCHOTT AG's silicone-free syriQ BioPure platform and Gerresheimer's ceramic pin approach for tungsten-sensitive products demonstrate the sector's commitment to solving compatibility challenges for sensitive biologics.

CMO Capacity Expansion Enabling Supply Scale Sterile injectable contract manufacturing organizations are expanding operations at pace, providing the fill-finish infrastructure that smaller biotech firms need to commercialize prefilled formats without major capital expenditure. These expansions, several of which involve nine-figure investments, are lowering the barrier to entry for new drug-device combination products and supporting forecast volume growth across the market.

Market Segmentation
The prefilled syringes market segments by syringe purpose, barrel material, chamber configuration, needle system, usability, syringe type, and packaging format, creating a detailed matrix for competitive positioning. Safety syringes account for approximately 70% of current market share, driven by healthcare system mandates around needlestick injury prevention. Disposable syringes capture 77% of the usability segment, with reusable prefilled syringes growing at a relatively faster pace as sustainability considerations enter procurement decisions. Glass barrel syringes dominate the material segment in 2026, preferred for their superior drug compatibility, particularly with sensitive biologics, while single-chamber syringes hold more than 70% of the chamber configuration segment. Dual-chamber syringes represent the faster-growing sub-segment, given their advantages for combination biologics requiring separate storage of liquid and lyophilized components.

By therapeutic area, blood disorders currently dominate, capturing close to 65% of the therapeutic syringes segment share. The cell therapy segment is positioned to grow at a faster pace than any other molecule type as cell-based medicines advance toward commercial scale. By syringe purpose, specialty prefilled syringes hold the highest share, reflecting the premium commanding power of devices engineered for specific high-value indications. The nested syringe packaging format holds majority market share in 2026, reflecting pharmaceutical manufacturers' preference for nest-and-tub systems that support automated fill-finish operations.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/prefilled-syringes-market/request-quote.html

Regional Insights
Europe commands the largest share of the global prefilled syringes market in 2026, accounting for approximately 50% of the total. This dominance reflects the region's advanced pharmaceutical manufacturing base, strong regulatory frameworks for drug-device combinations, and high penetration of biologic therapies for chronic diseases. More than 33% of prefilled syringe manufacturing facilities worldwide are based in Europe, giving the region both supply-side and demand-side advantages that are unlikely to erode materially through 2035.

North America holds the second-largest position, with companies headquartered in the region capturing approximately 24% of market share in 2026. The US market benefits from sophisticated healthcare infrastructure, strong patient safety standards that favor safety syringe adoption, and a robust pipeline of biologic and biosimilar approvals. Recent facility investments by Becton Dickinson and INCOG in the US underscore the confidence major manufacturers have in near-term demand.

Asia-Pacific is the fastest-growing region, with the market there projected to expand at a CAGR of 7% through 2035. Healthcare expenditure is rising across the region, chronic disease prevalence is increasing, and over 40% of global prefilled syringe manufacturing capacity is already based in Asia-Pacific. Emerging markets in BRICS nations, North Africa, and the Middle East are registering growth rates of 10-18% for prefilled syringes, according to channel feedback from major-market participants, pointing to a significant demand expansion wave that is only beginning.

Competitive Landscape
The prefilled syringes market features approximately 35 players with the capability to develop and manufacture these devices, creating a well-fragmented competitive structure that spans very large multinationals to specialized small companies. Key manufacturers profiled in the Roots Analysis report include Becton Dickinson and Company, Credence MedSystems, Gerresheimer, J.O. Pharma, Medefil, MedXL, Mitsubishi Gas Chemical, Nipro PharmaPackaging, Novartis, Pfizer, SCHOTT AG, Shandong Pharmaceutical Glass, Shandong Weigao, Stevanato, Taisei Kako, Vetter Pharma, and West Pharmaceutical Services, among more than 30 others. Key elastomeric closure suppliers include Aptar, Datwyler, Stevanato, and West Pharmaceutical, while fill-finish service providers such as Baxter BioPharma, Fresenius Kabi, Berkshire Sterile Manufacturing, and Emergent BioSolutions round out the ecosystem.

The primary competitive battlegrounds are materials science and needle safety innovation, fill-finish automation capability, and the ability to serve sensitive biologic formulations that require specialized container-closure systems. Large manufacturers are competing on both technology differentiation and geographic manufacturing scale, while specialized players carve positions in niche formats such as dual chamber and safety syringe configurations. Merger and acquisition activity remains a meaningful avenue for consolidation as larger companies seek to acquire fill-finish capacity and device engineering expertise simultaneously.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/prefilled-syringes-market/284.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.